Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and validation of blood tumor mutational burden reference standards.

Genes, chromosomes & cancer - 1 Mar 2023

Raiber-Moreau Eun-Ang, Portella Guillem, Butler Matthew G, Clement Omoshile, Konigshofer Yves, Hadfield James

Abstract excerpt

Tumor mutational burden (TMB), measured by exome or panel sequencing of tumor tissue or blood (bTMB), is a potential predictive biomarker for treatment benefit in patients with various cancer types receiving immunotherapy targeting checkpoint pathways. However, significant variability in TMB measurement has been observed. We developed contrived bTMB reference materials using DNA from tumor cell lines and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasms

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 36326821
DOI: 10.1002/gcc.23100
PMCID: PMC10107199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of blood tumor mutational burden reference standards.PMID 36326821Read ↗

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.Semantic proximity Read ↗

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsSemantic proximity Read ↗

Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.Semantic proximity Read ↗

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.Semantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.Semantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA MeasurementsSemantic proximity Read ↗

A somatic reference standard for cancer genome sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.